Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CrGluCl-A is a subunit of the glutamate-gated chloride channel (GluCl) found in the parasitic sea louse Caligus rogercresseyi, which is a significant pest in salmon aquaculture [1, 5]. As a member of the Cys-loop ligand-gated ion channel superfamily, it mediates inhibitory neurotransmission by allowing chloride ions to flow into neurons upon activation by the neurotransmitter glutamate [1, 2]. This receptor is a primary molecular target for avermectin-class antiparasitic drugs, such as ivermectin and emamectin, which act as allosteric activators to induce permanent channel opening and subsequent parasite paralysis [1, 4]. Research indicates that CrGluCl-A can form homomeric channels or heteromeric complexes with other subunits like CrGluCl-B, the latter of which can confer resistance to ivermectin [1, 5]. Understanding the functional properties and subunit composition of these channels is critical for managing drug resistance and developing novel treatment strategies in aquaculture settings [1, 5].
Allosteric activation of the chloride channel leading to hyperpolarization and paralysis.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate-gated chloride channel subunit alpha (CrGluCl-A).